Granules Pharmaceuticals, Inc. concludes US FDA Audit with Three Minor Observations

Granules India Limited announced that Granules Pharmaceuticals, Inc. (GPI), a wholly-owned foreign subsidiary of the company, located in Chantilly, Virginia, USA had undergone a Preapproval Inspection (PAI) by the US Food and Drug Administration (USFDA) from 24th to 28th January 2022.

The audit is a PAI for two of its product applications filed from this facility. The US FDA issued three minor observations during the audit conducted at the facility.

Commenting on the audit Ms. Priyanka Chigurupati, Executive Director, GPI, said "We are glad to have completed yet another audit with minor observations that we will respond to within the stipulated time period."

Shares of Granules India Limited was last trading in BSE at Rs. 300.50 as compared to the previous close of Rs. 294.10. The total number of shares traded during the day was 110379 in over 3894 trades.

The stock hit an intraday high of Rs. 307.90 and intraday low of 294.00. The net turnover during the day was Rs. 33397164.00.

Source : Equity Bulls

Keywords

GranulesIndia INE101D01020 GranulesPharmaceuticals Chantilly Virgina PreapprovalInspection USFDA